PURPOSE: Since there is a growing interest in preclinical research on interactions between radiation and cytotoxic agents, this study focused on the development of an alternative to the very laborious clonogenic assay (CA). METHODS: The colorimetric sulforhodamine B (SRB) assay was compared to the clonogenic assay for radiosensitivity testing in two lung cancer cell lines (A549, H292), one colon cancer cell line (HT-29) and one breast cancer cell line (MCF-7). In addition, the combination of the radiosensitizing agent gemcitabine and radiation was investigated with both assays. RESULTS: The dose-response curves obtained with the SRB assay and the CA were very similar up to 6 Gy. The radiosensitivity parameters (SF(2), alpha, beta, MID and ID(50)) obtained from the SRB assay and the CA were not significantly different between H292, A549 and MCF-7 cells. The radiation dose-response curves for A549 and H292 cells pretreated with 4 n M gemcitabine for 24 h clearly showed a radiosensitizing effect with both assays. The dose-enhancement factors obtained with the SRB assay and the CA were 1.80 and 1.76, respectively, for A549 cells, and 1.52 and 1.41 for H292 cells. CONCLUSIONS: The SRB assay was shown to be as useful as the more traditional CA for research on chemotherapy/radiotherapy interactions in cell lines with moderate radiosensitivity. This assay will be used for more extensive in vitro research on radiosensitizing compounds in these cell lines.
PURPOSE: Since there is a growing interest in preclinical research on interactions between radiation and cytotoxic agents, this study focused on the development of an alternative to the very laborious clonogenic assay (CA). METHODS: The colorimetric sulforhodamine B (SRB) assay was compared to the clonogenic assay for radiosensitivity testing in two lung cancer cell lines (A549, H292), one colon cancer cell line (HT-29) and one breast cancer cell line (MCF-7). In addition, the combination of the radiosensitizing agent gemcitabine and radiation was investigated with both assays. RESULTS: The dose-response curves obtained with the SRB assay and the CA were very similar up to 6 Gy. The radiosensitivity parameters (SF(2), alpha, beta, MID and ID(50)) obtained from the SRB assay and the CA were not significantly different between H292, A549 and MCF-7 cells. The radiation dose-response curves for A549 and H292 cells pretreated with 4 n M gemcitabine for 24 h clearly showed a radiosensitizing effect with both assays. The dose-enhancement factors obtained with the SRB assay and the CA were 1.80 and 1.76, respectively, for A549 cells, and 1.52 and 1.41 for H292 cells. CONCLUSIONS: The SRB assay was shown to be as useful as the more traditional CA for research on chemotherapy/radiotherapy interactions in cell lines with moderate radiosensitivity. This assay will be used for more extensive in vitro research on radiosensitizing compounds in these cell lines.
Authors: O Cosnefroy; A Tocco; P Lesbats; S Thierry; C Calmels; T Wiktorowicz; S Reigadas; Y Kwon; A De Cian; S Desfarges; P Bonot; J San Filippo; S Litvak; E Le Cam; A Rethwilm; H Fleury; P P Connell; P Sung; O Delelis; M L Andréola; V Parissi Journal: J Virol Date: 2011-10-19 Impact factor: 5.103
Authors: Takashi Yamatodani; Lars Ekblad; Elisabeth Kjellén; Anders Johnsson; Hiroyuki Mineta; Johan Wennerberg Journal: J Cancer Res Clin Oncol Date: 2008-09-24 Impact factor: 4.553
Authors: Xiaoying Liu; Wei Guo; Shuhong Wu; Li Wang; Ji Wang; Bingbing Dai; Edward S Kim; John V Heymach; Michael Wang; Luc Girard; John Minna; Jack A Roth; Stephen G Swisher; Bingliang Fang Journal: Biochem Pharmacol Date: 2012-02-22 Impact factor: 5.858
Authors: Tao Wang; Jiayi Huang; Mai Vue; Michael R Alavian; Hira Lal Goel; Dario C Altieri; Lucia R Languino; Thomas J FitzGerald Journal: Mol Cancer Res Date: 2018-09-28 Impact factor: 5.852
Authors: Steven H Lin; Jing Zhang; Uma Giri; Clifford Stephan; Mary Sobieski; Ling Zhong; Kathy A Mason; Jessica Molkentine; Howard D Thames; Stephen S Yoo; John V Heymach Journal: J Thorac Oncol Date: 2014-07 Impact factor: 15.609
Authors: An Wouters; Bea Pauwels; Filip Lardon; Greet G O Pattyn; Hilde A J Lambrechts; Marc Baay; Paul Meijnders; Jan B Vermorken Journal: BMC Cancer Date: 2010-08-19 Impact factor: 4.430
Authors: W Hu; W Hofstetter; W Guo; H Li; A Pataer; H H Peng; Z S Guo; D L Bartlett; A Lin; S G Swisher; B Fang Journal: Cancer Gene Ther Date: 2008-06-06 Impact factor: 5.987
Authors: B Pauwels; J B Vermorken; A Wouters; J Ides; S Van Laere; H A J Lambrechts; G G O Pattyn; K Vermeulen; P Meijnders; F Lardon Journal: Br J Cancer Date: 2009-08-18 Impact factor: 7.640